US Patent
US8545884 — Solid pharmaceutical formulations comprising BIBW 2992
Formulation · Assigned to Boehringer Ingelheim International GmbH · Expires 2029-12-19 · 4y remaining
Vulnerability score
36/100
Strong — defensible against typical IPR challenges
What this patent protects
This patent protects solid pharmaceutical formulations of BIBW 2992 dimaleate salt, providing an immediate release profile of the active substance.
USPTO Abstract
The present invention relates to a pharmaceutical dosage form containing the active substance BIBW 2992 as the dimaleate salt, providing an immediate release profile of the active substance, further, the invention relates to compacted intermediates comprising BIBW 2992 dimaleate salt (BIBW 2992 MA 2 ) in form of a powder prepared using a combined roller compaction and sieving step from BIBW 2992 MA 2 , intermediate blends prepared from said compacted intermediate as well as solid oral formulations providing an immediate release profile of the active substance, made from said compacted intermediate or from said intermediate blends ready for use/ingestion, e.g. capsule and tablet formulations such as uncoated or film-coated tablets prepared by direct-compression, and methods for their production.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.